CHAPEL HILL, N.C.--(BUSINESS WIRE)--iOrganBio today announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along ...
Challenges include the optimization of vector design, the control of bioreactor conditions, and the end-to-end integration of workflows However, cell therapies, defined as those where a patient is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback